This $1,552,348 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research by the Children's Mercy Hospital in Kansas City, Missouri to investigate the role of the SH3BP2 protein in the immunopathogenesis of nephrotic syndrome. The award period runs from September 1, 2024 to August 31, 2028. As a recipient of numerous federal grants and contracts, Children's Mercy Hospital conducts cutting-edge pediatric research and clinical trials focused on advancing healthcare outcomes. This specific project aims to advance the understanding of immune activation mechanisms underlying nephrotic syndrome, a serious kidney disorder in children, with the goal of developing new treatments.